24 results
6-K
EX-99.1
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
frexalimab-treated group were COVID-19 (n=5 [9.8%] in the lower-dose group; all uncomplicated cases of mild or moderate intensity) and headache (n=1
6-K
EX-99.2
SNY
Sanofi
2 Jun 23
Approval of the financial statements for the fiscal year 2022
10:53am
(≥4%) in any frexalimab-treated group were COVID-19 (n=5 [9.8%] in the lower-dose group; all uncomplicated cases of mild or moderate intensity
6-K
EX-99.1
SNY
Sanofi
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
.
Sanofi upgraded its scope 3 GHG emission reductions ambition to -30% by 2030, unveiling low energy intensity vaccines facility
Key milestone … reduction target for validation.
Evolutive Vaccine Facility in Singapore: low energy intensity and 100% electrified by design
Building a path
6-K
EX-99.2
SNY
Sanofi
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
last May.
Evolutive Vaccine Facility in Singapore: low energy intensity and 100% electrified by design
Building a path towards carbon neutrality
6-K
EX-99.2
SNY
Sanofi
13 Jul 22
Current report (foreign)
1:40pm
alfa prophylaxis resulted in statistically significant and clinically meaningful improvements in physical health, pain intensity and joint health … meaningful improvements in physical health (p=0.0001), pain intensity (p=0.0276), and joint health (p=0.0101) when comparing week 52 and baseline
6-K
EX-99.1
92ee7itx2faxt frny
4 Apr 22
Distribution of Shares of Euroapi
11:21am
6-K
EX-99.1
rlo9y
11 May 21
Q1 2021 sales increase driven by growth drivers Dupixent® and Vaccines
10:01am
6-K
EX-99.1
crb11ya3n9605ajtihq
28 Apr 21
Q1 2021 sales increase of 2.4% at CER driven by growth drivers Dupixent® and Vaccines
9:49am
6-K
EX-99.1
7zcqora 4m82rq0
3 Dec 20
Current report (foreign)
1:40pm
6-K
EX-99.1
n5rdi4
25 Nov 20
European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
12:40pm
6-K
EX-99.1
v782qmf0vy
29 Oct 20
Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
10:22am
6-K
EX-99.2
5ja94fr
27 May 20
Sanofi announces pricing of Regeneron stock offering
11:38am
6-K
EX-99.3
9ntw5eydow94lzhlc2c9
7 Apr 20
Current report (foreign)
1:49pm
6-K
EX-99.2
0tlp9s
9 Aug 19
Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
8:22am
6-K
EX-99.1
7a680lg
29 Apr 19
FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
10:57am
6-K
EX-99.1
okk41l7 cq
19 Mar 19
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
10:15am
6-K
EX-99.1
o4zji26ke3wjac
4 Feb 19
CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
8:53am
6-K
EX-99.1
yvpalq 2yjnslsls0n
13 Nov 18
ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause
6:20am
6-K
EX-99.1
y73ucdft6hz
25 Oct 11
Current report (foreign)
12:00am
6-K
EX-99.2
o02qp2nebzcrc9n
2 Jul 07
Current report (foreign)
12:00am